Developer docs
API playgroundTry for free, no card

Search company profiles

Functional Neuromodulation

Full company profile

uuid0009ouq

Namestring
Functional Neuromodulation
Websiteurl
fxneuromod.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Functional Neuromodulation is a privately held medical technology company founded in 2010 and headquartered in Toronto, Canada, that is developing neuromodulation technologies targeting cognitive and memory disorders. The company's work sits within the deep brain stimulation (DBS) device market, which independent market intelligence projects will reach $2.94 billion by 2030 at an 11.6% annual growth rate, suggesting a substantial long-term addressable opportunity for cognitive-indication neuromodulation. The company is scientifically anchored by Dr. Andres Lozano, who serves as Founding Scientist, Chairman of the Scientific Advisory Board, and Director — a leadership structure typical of academic spin-out ventures translating deep brain stimulation research into clinical applications.

The company's only disclosed financing to date was a $10.4 million round closed in October 2011, led by Medtronic with participation from Genesys Capital. The involvement of Medtronic, the dominant incumbent in DBS hardware, is strategically significant and may indicate a future commercial partnership, licensing pathway, or acquisition route. With 1-10 employees and no publicly disclosed product, pricing, customer base, or revenue, the company appears to operate as a small, research- and clinical-stage organization rather than a commercial entity.

No product specifications, regulatory milestones, clinical trial readouts, intellectual property portfolio, geographic footprint, or go-to-market details are present in the available source material. As a result, the company's current stage of development, burn rate, pipeline composition, and commercialization timeline cannot be verified from public information alone. Investors evaluating Functional Neuromodulation should treat it as a thinly disclosed, early-stage clinical venture and seek primary information from the company, clinical trial registries, and regulatory filings before forming a view on execution risk.

Short descriptiontext

Functional Neuromodulation is a privately held Toronto-based medical technology company, founded in 2010, developing neuromodulation technologies for cognitive and memory disorders within the deep brain stimulation device market.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMinneapolis, United States
HQ citystring
Minneapolis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
deep brain stimulation, neuromodulation devices, cognitive disorder therapy, memory disorder treatment, neural implant technology
Industry1 code
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Deep Brain Stimulation Devices
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Functional Neuromodulation is a medical technology company developing neuromodulation technologies targeting cognitive and memory disorders. The company focuses on deep brain stimulation (DBS) approaches intended to treat conditions such as Alzheimer's disease and related cognitive impairments. The firm operates in the DBS device market, which is projected to reach $2.94 billion by 2030 at an 11.6% annual growth rate.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product or service information is available from the provided sources. The available source data consists of a limited webpage fragment (tracking pixel and cookie consent link only) and two market-context news articles about the deep brain stimulation device market, which do not contain specific product details for Functional Neuromodulation.

Product and service1 record
1Deep Brain Stimulation (DBS) Technology for Cognitive Disorders
CategoryNeuromodulation Devices
Description

Neuromodulation technology platform targeting cognitive and memory disorders such as Alzheimer's disease, intended for use by clinicians and patients with cognitive impairments, developed within the deep brain stimulation device market.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Abbott
TypeBroad incumbent
Description

Through its St. Jude acquisition, Abbott markets the Infinity DBS system. A primary DBS incumbent with comparable neurostimulation infrastructure and R&D programs.

TypeBroad incumbent
Description

Global leader in implantable DBS systems (Activa) and lead investor in Functional Neuromodulation's 2011 round. Direct incumbent in DBS hardware with overlapping cognitive-disorder research interests.

TypeBroad incumbent
Description

Markets the Vercise DBS system and is actively investing in next-generation directional and sensing-enabled DBS. Another top-3 DBS incumbent competing for cognitive-indication opportunities.

TypeDirect peer
Description

Develops the RNS System, an implantable closed-loop neurostimulator for epilepsy. Comparable as a venture-backed, indication-focused implantable brain neuromodulation company.

TypeDirect peer
Description

Markets Vagus Nerve Stimulation (VNS) systems for epilepsy and treatment-resistant depression. Comparable as an implantable neuromodulation company pursuing CNS indications adjacent to cognition/behavior.

TypeEmerging player
Description

Implantable neurostimulation (hypoglossal nerve stimulation) for obstructive sleep apnea. Comparable as a venture-backed implantable neurostim developer that scaled from small team to public company.

7Axonics
TypeEmerging player
Description

Develops sacral neuromodulation implants for incontinence. Comparable as a focused, venture-backed implantable neurostimulation company pursuing a specific high-unmet-need indication.

TypeEmerging player
Description

Markets 10 kHz high-frequency spinal cord stimulation systems for chronic pain. Comparable as an implantable neurostimulation company focused on a specific therapeutic application.

TypeEmerging player
Description

Developing bioelectronic VNS therapy for inflammatory autoimmune diseases. Comparable as a venture-backed company applying implantable neurostimulation to non-traditional indications.

10MicroPort Scientific
TypeBroad incumbent
Description

Acquired LivaNova's CRM/neuromodulation business and continues to develop DBS systems (e.g., Beijing Puhua license). Comparable as a broad incumbent now competing in the DBS market.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Functional Neuromodulation

Deep Brain Stimulation Devicesfxneuromod.com

Functional Neuromodulation is a privately held Toronto-based medical technology company, founded in 2010, developing neuromodulation technologies for cognitive and memory disorders within the deep brain stimulation device market.

What Functional Neuromodulation does

Functional Neuromodulation is a privately held medical technology company founded in 2010 and headquartered in Toronto, Canada, that is developing neuromodulation technologies targeting cognitive and memory disorders. The company's work sits within the deep brain stimulation (DBS) device market, which independent market intelligence projects will reach $2.94 billion by 2030 at an 11.6% annual growth rate, suggesting a substantial long-term addressable opportunity for cognitive-indication neuromodulation. The company is scientifically anchored by Dr. Andres Lozano, who serves as Founding Scientist, Chairman of the Scientific Advisory Board, and Director — a leadership structure typical of academic spin-out ventures translating deep brain stimulation research into clinical applications.

The company's only disclosed financing to date was a $10.4 million round closed in October 2011, led by Medtronic with participation from Genesys Capital. The involvement of Medtronic, the dominant incumbent in DBS hardware, is strategically significant and may indicate a future commercial partnership, licensing pathway, or acquisition route. With 1-10 employees and no publicly disclosed product, pricing, customer base, or revenue, the company appears to operate as a small, research- and clinical-stage organization rather than a commercial entity.

No product specifications, regulatory milestones, clinical trial readouts, intellectual property portfolio, geographic footprint, or go-to-market details are present in the available source material. As a result, the company's current stage of development, burn rate, pipeline composition, and commercialization timeline cannot be verified from public information alone. Investors evaluating Functional Neuromodulation should treat it as a thinly disclosed, early-stage clinical venture and seek primary information from the company, clinical trial registries, and regulatory filings before forming a view on execution risk.

Functional Neuromodulation firmographics

Firmographics
Name
Functional Neuromodulation
Website
https://fxneuromod.com
Company type
Private
Founded year
2011
Headcount range
1–10 employees
Short description
Functional Neuromodulation is a privately held Toronto-based medical technology company, founded in 2010, developing neuromodulation technologies for cognitive and memory disorders within the deep brain stimulation device market.
Ownership category
akta.pro rank

Functional Neuromodulation industry classification

Industry
Product category
Deep Brain Stimulation Devices
NAICS
Scientific Research and Development Services (5417)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Deep brain stimulation
  • Neuromodulation devices
  • Cognitive disorder therapy
  • Memory disorder treatment
  • Neural implant technology

Where Functional Neuromodulation is headquartered

Location

Headquarters

HQ city
Minneapolis
HQ country
United States
HQ region
North America

Markets served

Functional Neuromodulation business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Functional Neuromodulation product offering

Product offering

Core offering

Functional Neuromodulation is a medical technology company developing neuromodulation technologies targeting cognitive and memory disorders. The company focuses on deep brain stimulation (DBS) approaches intended to treat conditions such as Alzheimer's disease and related cognitive impairments. The firm operates in the DBS device market, which is projected to reach $2.94 billion by 2030 at an 11.6% annual growth rate.

Product overview

No product or service information is available from the provided sources. The available source data consists of a limited webpage fragment (tracking pixel and cookie consent link only) and two market-context news articles about the deep brain stimulation device market, which do not contain specific product details for Functional Neuromodulation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Deep Brain Stimulation (DBS) Technology for Cognitive Disorders Neuromodulation technology platform targeting cognitive and memory disorders such as Alzheimer's disease, intended for use by clinicians and patients with cognitive impairments, developed within the deep brain stimulation device market.

Companies that use Functional Neuromodulation

Customer profile

Ideal customer profiles2 records

Functional Neuromodulation technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Functional Neuromodulation partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Expansion highlights2 records

Functional Neuromodulation competitors and assessment

Company assessment

Broad incumbents

  • Abbott: Through its St. Jude acquisition, Abbott markets the Infinity DBS system. A primary DBS incumbent with comparable neurostimulation infrastructure and R&D programs.
  • Medtronic: Global leader in implantable DBS systems (Activa) and lead investor in Functional Neuromodulation's 2011 round. Direct incumbent in DBS hardware with overlapping cognitive-disorder research interests.
  • Boston Scientific: Markets the Vercise DBS system and is actively investing in next-generation directional and sensing-enabled DBS. Another top-3 DBS incumbent competing for cognitive-indication opportunities.
  • MicroPort Scientific: Acquired LivaNova's CRM/neuromodulation business and continues to develop DBS systems (e.g., Beijing Puhua license). Comparable as a broad incumbent now competing in the DBS market.

Direct peers

  • NeuroPace: Develops the RNS System, an implantable closed-loop neurostimulator for epilepsy. Comparable as a venture-backed, indication-focused implantable brain neuromodulation company.
  • LivaNova: Markets Vagus Nerve Stimulation (VNS) systems for epilepsy and treatment-resistant depression. Comparable as an implantable neuromodulation company pursuing CNS indications adjacent to cognition/behavior.

Emerging players

  • Inspire Medical Systems: Implantable neurostimulation (hypoglossal nerve stimulation) for obstructive sleep apnea. Comparable as a venture-backed implantable neurostim developer that scaled from small team to public company.
  • Axonics: Develops sacral neuromodulation implants for incontinence. Comparable as a focused, venture-backed implantable neurostimulation company pursuing a specific high-unmet-need indication.
  • Nevro: Markets 10 kHz high-frequency spinal cord stimulation systems for chronic pain. Comparable as an implantable neurostimulation company focused on a specific therapeutic application.
  • SetPoint Medical: Developing bioelectronic VNS therapy for inflammatory autoimmune diseases. Comparable as a venture-backed company applying implantable neurostimulation to non-traditional indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Functional Neuromodulation social profiles

Digital presence

Functional Neuromodulation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Functional Neuromodulation leadership team

Management profile

Number of profiles

Profiles1 record

Functional Neuromodulation funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Functional Neuromodulation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Functional Neuromodulation

What does Functional Neuromodulation do?

Functional Neuromodulation is a medical technology company developing neuromodulation technologies targeting cognitive and memory disorders. The company focuses on deep brain stimulation (DBS) approaches intended to treat conditions such as Alzheimer's disease and related cognitive impairments. The firm operates in the DBS device market, which is projected to reach $2.94 billion by 2030 at an 11.6% annual growth rate.

When was Functional Neuromodulation founded?

Functional Neuromodulation was founded in 2011. It employs 1 to 10 people.

Where is Functional Neuromodulation based?

Functional Neuromodulation is headquartered in Minneapolis, United States, in the North America region.

Who are Functional Neuromodulation's main competitors?

Broad incumbents on record are Abbott, Medtronic, Boston Scientific and MicroPort Scientific. Direct peers are NeuroPace and LivaNova. Emerging players are Inspire Medical Systems, Axonics, Nevro and SetPoint Medical.

Does Functional Neuromodulation have an API?

No public API is recorded for Functional Neuromodulation.

What industry is Functional Neuromodulation in?

Functional Neuromodulation's product category is Deep Brain Stimulation Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 5417 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireFunctional Neuromodulation Announces Breakthrough Device Designation from the U.S. FDA for Deep Brain Stimulation for Alzheimer's DiseaseFunctional Neuromodulation has received Breakthrough Device designation from the U.S. FDA for the Vercise Deep Brain Stimulation Systems, developed and manufactured by Boston Scientific Corporation, as an adjunctive treatment for patients 65 years and older with mild probable Alzheimer's disease. The company's ADvance II pivotal study is currently enrolling up to 210 patients in a randomized controlled trial at 20 study sites across the United States, Canada, and Germany. The Breakthrough Device designation provides priority review status to help accelerate the path toward FDA approval for this treatment, which aims to address the urgent unmet need for new Alzheimer's therapies given the limitations of existing pharmacological approaches.PR NewswireTodd Langevin Appointed As Executive ChairmanNewronika, a spin-off of Policlinico of Milan and University of Milan specializing in neuromodulation, has appointed Todd Langevin as Executive Chairman. Langevin brings over 30 years of neuromodulation experience including 20 years at Medtronic and currently serves as CEO of Functional Neuromodulation Ltd developing DBS treatment for Alzheimer's disease. The appointment coincides with Newronika's First-in-Man clinical study in Europe and preparation for FDA IDE approval for its closed-loop DBS system, which the company claims is the first of its kind for Parkinson's disease patients.PR NewswireFunctional Neuromodulation Initiates Pivotal Clinical Trial of Deep Brain Stimulation for Alzheimer's DiseaseFunctional Neuromodulation has initiated the ADvance II Study, a pivotal global clinical trial evaluating deep brain stimulation of the fornix as a treatment for patients with mild Alzheimer's Disease. The randomized, double-blind, controlled trial will enroll up to 210 participants aged 65 and older across 14 sites in the United States, Canada, and Germany, using Boston Scientific's Vercise Directional System. This Phase III-equivalent trial seeks to determine whether DBS-f can drive neural activity to produce better clinical outcomes for Alzheimer's, a disease affecting over 30 million people worldwide with annual societal costs approaching $1 trillion.PR NewswireFunctional Neuromodulation Announces CEO Leadership TransitionFunctional Neuromodulation Ltd. announced that Todd Langevin has succeeded Vincent Owens as Chief Executive Officer effective January 25, 2019, with Owens remaining as Executive Chairman. Langevin, who previously served as President and Chief Operating Officer since the company's formation in 2011, brings over two decades of medical device experience including senior roles at Medtronic and CVRx. The leadership transition comes as the company prepares to begin enrollment in the ADvance II pivotal clinical study of its DBS-f deep brain stimulation therapy for mild Alzheimer's disease, following prior FDA IDE approval.FinSMEsFunctional Neuromodulation Closes $600K Seed FinancingFunctional Neuromodulation, a Toronto-based DBS therapy startup for Alzheimer's and MCI, closed $600,000 in seed financing from Genesys Capital. The funding brings Genesys partner Kelly Holman onto the board, and the company plans a Series A next year to advance a Phase II trial.